Persistent injection site nodules from exenatide: Successful treatment with intralesional triamcinolone

[1]  V. Ricotti,et al.  Severe persistent injection site reactions after subcutaneous 2′-O-methyl phosphorothioate oligonucleotide therapy for Duchenne muscular dystrophy , 2017, Neuromuscular Disorders.

[2]  A. Brinker,et al.  Injection-Site Nodules Associated With the Use of Exenatide Extended-Release Reported to the U.S. Food and Drug Administration Adverse Event Reporting System , 2015, Diabetes Spectrum.

[3]  Á. Santos-Briz,et al.  Exenatide-Induced Eosinophil-Rich Granulomatous Panniculitis: A Novel Case Showing Injected Microspheres. , 2015, The American Journal of dermatopathology.

[4]  Ying Guo,et al.  Exenatide-induced eosinophilic sclerosing lipogranuloma at the injection site. , 2014, The American Journal of dermatopathology.

[5]  M. Stone,et al.  Eosinophil‐rich granulomatous panniculitis caused by exenatide injection , 2014, Journal of cutaneous pathology.

[6]  J. Malloy,et al.  Efficacy, Safety, and Tolerability of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus: An Integrated Analysis of the DURATION Trials , 2013, Postgraduate medicine.

[7]  S. Mudaliar,et al.  Send Orders of Reprints at Reprints@benthamscience.net Evolution of Exenatide as a Diabetes Therapeutic , 2022 .

[8]  M. Trautmann,et al.  Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. , 2011, Diabetes technology & therapeutics.

[9]  R. Gentilella,et al.  Exenatide: a review from pharmacology to clinical practice , 2009, Diabetes, obesity & metabolism.

[10]  R. Sengelmann,et al.  Vitamin B12‐Associated Localized Scleroderma and Its Treatment , 2004, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].